Locations/Topics/Faculty

Birmingham, AL - Date: Friday, May 9, 2008 6:00pm EST -8:00 pm EST
Birmingham Marriott
3590 Grandview Parkway
Birmingham, AL 35243

Greg Mishkel, MD
Prairie Cardiovascular Consultants, Ltd
Springfield, IL

James Hermiller, MD
The Care Group
Indianapolis, IN

---

This activity is sponsored by the North American Center for Continuing Medical Education.

---

This activity is supported by an educational grant from Abbott Vascular

---

Target Audience:

Physicians who treat patients with vascular disease

---

Learning Objectives:

Upon completion of this educational activity, participants should be able to:
• describe the current outcomes data with current generation drug-eluting stents (DES) and their limitations
• describe the design, pharmacokinetics, and current outcomes data with the next group of commercialized DES in the United States
• discuss the safety profile of first and second generation DES
• describe the relative efficacy and deliverability of first and second generation DES
• discuss the Endeavor trials
• appropriately utilize DES in clinically relevant settings in the management of patients with stale and unstable angina
• describe the advantages and disadvantages of DES versus bare metal stents (BMS) in a broad range of patients and coronary artery lesions (the relative contraindications to DES deployment will be discussed)
• recognize the importance of long-term dual antiplatelet therapy in the setting of DES deployment
• describe the characteristics of new BMS that impact favorably on restenosis
• appropriately treat lesions with BMS or DES
• review the latest data on the safety and efficacy for DES in both the on-label and off-label clinical situation
• identify specific patient populations whereby the decision-making regarding the utilization of DES versus BMS may change.

---

Accreditation:

MD/DO: This activity is sponsored by the North American Center for Continuing Medical Education (NACCME). NACCME is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians. NACCME designates this educational activity for a maximum of 1 AMA PRA Category 1 Credit™. Physicians should only claim credit commensurate with the extent of their participation in the activity. This activity has been planned and produced in accordance with the ACCME Essential Areas and Policies.

---

Disclosure Policy:

Off-Label/Unapproved Usage Disclosure:
Off-Label/Unapproved Usage Discussion This educational activity contains discussion of published and/or investigational uses of agents that are not indicated by the US Food and Drug Administration. Neither NACCME, Cordis, Boston Scientific, Medtronic, nor Abbott recommends the use of any agent outside of the labeled indications. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

Disclosures:
Faculty and all others who have the ability to control the content of continuing medical education activities sponsored by NACCME are expected to disclose whether they do or do not have any real or apparent conflict(s) of interest or other relationships related to the content of their presentation(s). It is not assumed that these financial interests or affiliations will have an adverse impact on faculty presentations.